COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03259308
Recruitment Status : Terminated (Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.)
First Posted : August 23, 2017
Last Update Posted : December 11, 2020
Information provided by (Responsible Party):
Takeda ( Shire )

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : July 15, 2020
Actual Study Completion Date : October 6, 2020